Dicot nomination committee appointed for AGM 2020

According to the instruction that was adopted at the Dicot AN (Publ) AGM May 16, 2019, the nomination committee should consist of three members. 

November 26, 2019, Uppsala, Sweden – Dicot AB (publ) (“Dicot” or the “Company”) The Nomination Committee, which is to be appointed for the period until a new Nomination Committee has been appointed, will have three members, which will be appointed by the three largest shareholders of the company in terms of votes.

As soon as reasonably possible after the end of the third quarter, the Chairman of the Board should contact the three largest shareholders in terms of votes recorded in the share register maintained by Euroclear Sweden AB and request that within a reasonable time in the circumstances, although not more than 30 days, they state the name of the individual such shareholder wishes to appoint as a member of the Nomination Committee. If one of the three largest shareholders does not wish to exercise its entitlement to appoint a member of the Nomination Committee, the next shareholder in turn will be offered the entitlement to appoint a member of the Nomination Committee.

The committee shall appoint a Chairman of the Nomination Committee within itself. The Chairman of the Board or other Director may never serve as Chairman of the Nomination Committee.

Based on the above, and as of September 30, 2019, the nomination committee for the 2020 AGM has been determined to consist of the following persons: 

•  Jarl Wikberg
•  Bengt Walfridsson
•  Bertil Lindkvist  

The suggestion from the nomination committee will be presented in the notice to the AGM 2020 as well as on the Company website, https://www.dicot.se/ 

Shareholders who wish to leave suggestions to the nomination committee are welcome to contact the nomination committee at the Company address. In order for the nomination committee to take a suggestion into account, the suggestion must have been received in a timely manner before the AGM, January 31, 2020 at the latest. 

For further information, please contact:

Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
E-mail: julie.silber@dicot.se
www.dicot.se

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 26, 2019.

About Dicot AB

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to esnrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.